Small molecule · Inhibitor of CDK9 · developed by Sellas Life Sciences Group
Tambiciclib is a selective CDK9 inhibitor that blocks phosphorylation and kinase activity of CDK9, preventing PTEFb-mediated activation of RNA polymerase II. This inhibits transcription of anti-apoptotic proteins, inducing cell cycle arrest and apoptosis in tumor cells. It is studied in hematologic malignancies including acute myeloid leukemia and chronic B-cell lymphocytic leukemia.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04588922 | Phase 1/2 | Hematologic Malignancies | Recruiting | SLS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hematologic Malignancies
See SLS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SLS catalysts and pipeline →